Editor

8393 POSTS
0 COMMENTS

LYMPHIR Launches in U.S., Bringing New Possibility for Stage 1 to three CTCL

The U.S. business launch of LYMPHIR (denileukin diftitox-cxdl), a novel most cancers immunotherapy for adults with relapsed or refractory stage 1 to...

What Sufferers Ought to Know About EGFR Mutated Lung Most cancers Therapy

Dr. Girindra Raval sat down for an interview with CURE to debate what sufferers with EGFR-mutated lung most cancers ought to learn...

Navigating A number of Myeloma Therapy: What Sufferers Want To Know

Relapsed and refractory a number of myeloma will be troublesome to handle, particularly as sufferers progress by way of a number of...

Breaking Down Therapy Developments for Small Cell Lung Most cancers

Throughout the CURE Educated Affected person® Lung Most cancers Summit, held in tandem with the 2025 PER® New York Lung Most cancers...

Each FDA Oncology Approval From November 2025

In November 2025, the U.S. Meals and Drug Administration (FDA) issued a number of approvals throughout oncology and supportive care. These choices...

Editor

8393 POSTS
0 COMMENTS
spot_img